BridgeBio Pharma, Inc.(BBIO)Earnings, Financials & Key RatiosBridgeBio Pharma, Inc. (BBIO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's reliance on external financing to support its $197.3 million quarterly cash burn and the accumulation of $3.4 billion in debt present substantial risks to shareholder value.
BridgeBio Pharma, Inc. (BBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
BridgeBio Pharma, Inc. (BBIO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.84vs $0.68-23.8% | $195Mvs $178M+9.2% |
| Q1 2026 | Feb 24, 2026 | $1.00vs $0.71-40.2% | $154Mvs $147M+5.0% |
| Q4 2025 | Oct 29, 2025 | $0.95vs $0.88-8.0% | $121Mvs $148M-18.5% |
| Q3 2025 | Aug 5, 2025 | $0.95vs $0.83-14.5% | $111Mvs $108M+2.3% |
Recent stock market news and headlines for BridgeBio Pharma, Inc. (BBIO)
- Phase 3 PROPEL 3 data published today in NEJM were simultaneously presented at ICCBH in a late-breaking oral presentation; presentation includes new arm span Z-score data showing a statistically significant improvement versus placebo (LS mean +0.37 SD; p
PALO ALTO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that on June 18, 2026, the compensation committee of BridgeBio's board of directors approved equity grants to 30 new employees in restricted stock units for an aggregate of 66,810 shares of the Company's common stock. One-fourth of the shares underlying each employee's restricted stock units will vest on May 16, 2027, with one-twelfth of the remaining shares underlying each such employee's restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee's continued employment with the Company or one of its subsidiaries on such vesting dates.
PALO ALTO, Calif., June 22, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage, multi-product biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional positive data from PROPEL 3, the global Phase 3 pivotal study of oral infigratinib in children living with achondroplasia, will be shared in a late breaking oral presentation at the International Congress of Children's Bone Health (ICCBH) 2026 taking place in Montreal, Canada on June 27-30, 2026.
Key metrics vs top competitors for BridgeBio Pharma, Inc. (BBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $77.91 | $15.26B | -20.56 | 126.26% | -145.26% | — | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $6.62 | $1.02B | -9.07 | 40.22% | -5.56% | -20.64% | — | |
| $30.25 | $3.05B | -9.19 | -4.26% | -156.36% | -68.97% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — | |
| $522.25 | $132.84B | 34.09 | 9.57% | 35.4% | 23.93% | — |
BridgeBio Pharma, Inc. (BBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BridgeBio Pharma, Inc. (BBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 13, 2026·SEC
May 8, 2026·SEC
May 7, 2026·SEC
Get notified when BBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BridgeBio Pharma, Inc. (BBIO) stock FAQ — growth, dividends, profitability & financials explained
BridgeBio Pharma, Inc. (BBIO) reported $580.0M in revenue for fiscal year 2025.
BridgeBio Pharma, Inc. (BBIO) grew revenue by 126.3% over the past year. This is strong growth.
BridgeBio Pharma, Inc. (BBIO) reported a net loss of $725.9M for fiscal year 2025.
BridgeBio Pharma, Inc. (BBIO) had negative free cash flow of $454.1M in fiscal year 2025, likely due to heavy capital investments.
